Role of posaconazole in the treatment of oropharyngeal candidiasis

Voichita Ianas1
Kathryn R Matthias2
Stephen A Klotz1

1Section of Infectious Diseases and Department of Medicine, 2School of Pharmacy, University of Arizona, Tucson, Arizona, USA

Abstract: Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi. It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treating deep-seated infections. It is used routinely and effectively for the prophylaxis of invasive fungal infections in immunosuppressed hosts and is an effective treatment of oropharyngeal candidiasis, including azole-resistant disease.

Keywords: posaconazole, azole, yeasts, filamentous fungi

Overview of oropharyngeal candidiasis

The frequency of Candida species infections in humans continues to increase. There are many manifestations of the disease, some trivial and some life-threatening. The most common candidal infection is mucocutaneous oropharyngeal candidiasis (OPC). Thrush is the classic lesion of OPC and is recognized by the presence of creamy white, curd-like patches on the soft and hard palate and other oral mucosal surfaces. Diagnosis is confirmed by scraping one of the lesions and using potassium hydroxide or Gram stain of scraped material which on microscopy demonstrates hyphae, pseudohyphae, and/or yeast forms with scattered polymorphonuclear leukocytes. The fungi are usually entangled with Gram positive cocci.1 Other manifestations of OPC include atrophy of the tongue or acute atrophic candidiasis, “denture sore mouth” or chronic atrophic candidiasis (inflammation under the dental plates), angular cheilitis (inflammation at the corners of the mouth), and Candida leukoplakia (firm, white patches, persistently present on the oral mucosa).2

The Candida species commonly associated with OPC is C. albicans.2 In human immunodeficiency virus (HIV)-positive individuals, C. albicans is isolated in over 70% of the patients, and less often C. glabrata, C. tropicalis, C. parapsilosis,3 or C. dublinensis are found.4 OPC is common in HIV-positive patients with CD4 counts lower than 200 cells/μL, immunocompromised patients on chemotherapy, patients on systemic steroids, or patients who use inhaled steroids. Approximately 80%–90% of patients with acquired immunodeficiency syndrome (AIDS) will develop OPC.5

Preferred therapy for OPC differs by patient population. For example, therapy in the HIV patient may differ from that in a patient with immunosuppression secondary to steroids or chemotherapy. In HIV-negative patients with mild OPC, treatment consists of
local antifungal lozenges or solutions, eg, nystatin swish and swallow four times a day or clotrimazole troches (one 10 mg troche five times daily). If local therapy does not work, oral therapy is recommended, such as fluconazole 200 mg once daily, then 100–200 mg daily. These recommendations are derived from a consensus of authorities, with moderate evidence for or against the use of a regimen based upon more than one well-designed clinical study. Recurrence is common if underlying risk factors are still present (eg, continued use of steroids or chemotherapy). In HIV-positive patients with OPC, treatment also varies depending on the severity of disease. Topical agents can be used in mild OPC, but oral azoles are indicated in moderate to severe OPC. Antiretroviral drugs are essential in the treatment and eradication of OPC in AIDS patients; if antiretrovirals are not started, the rate of relapse is high. Topical treatment has no role if esophageal candidiasis is present.

**Microbiological aspects of posaconazole**

Posaconazole is a triazole antifungal agent that has structural similarities to itraconazole. Posaconazole inhibits the synthesis of ergosterol (a sterol component of fungal cell membranes) by inhibition of the enzyme, lanosterol 14-alpha demethylase, with accumulation of methylated sterol precursors. In contrast with other azole antifungals, posaconazole is not extensively metabolized by the CYP450 enzymes. In *vitro* tests have shown posaconazole to be active against *Candida* species, *Aspergillus* species, *Coccidioides* species, *Fusarium* species, *Histoplasma capsulatum*, *Zygomycetes*, *Phaeohyphomycetes*, and other filamentous fungi. In addition, posaconazole has demonstrated activity against fluconazole- and itraconazole-resistant *Candida* species, as well as itraconazole-, voriconazole-, and amphotericin B-resistant *Aspergillus fumigatus*, and activity against *Cryptococcus neoformans*. Posaconazole is fungistatic against some *Candida* species (C. *albicans*, C. *glabrata*, C. *parapsilosis*, and C. *tropicalis*), but is fungicidal against other *Candida* species (C. *lusitaniae*, C. *krusei*, C. *kefyr*, and C. *inconspicua*). Clinical uses of posaconazole that are Food and Drug Administration (FDA)-approved include prophylaxis of invasive aspergillosis in high-risk patients, prophylaxis of disseminated candidiasis in severely immunocompromised patients, and treatment of OPC, including the treatment of OPC refractory to itraconazole and/or fluconazole. Clinical applications that are not FDA-approved include invasive aspergillosis or esophageal candidiasis.

**OPC treatment and a comparator drug, fluconazole**

Fluconazole is a triazole with greater than 90% bioavailability after oral administration and has been extensively used for treatment of a wide range of *Candida* infections, in particular, OPC. Although OPC usually responds to fluconazole, if underlying predisposing factors are not corrected, OPC can recur. There have been a number of reports of fluconazole failure or resistance in AIDS patients. However, it is difficult to establish a definition of resistance. In some cases, the term is used when a patient fails to respond clinically to antifungal therapy, and in other cases, resistance is described by the minimum inhibitory concentration (MIC) of the drug. While correlations between the fluconazole MIC and outcome have been established in animal models, therapeutic failures and successes in humans may be seen with isolates for which MICs are both high and low. MIC breakpoints for fluconazole remain unclear, but the Clinical and Laboratory Standards Institute methodology recommends the following breakpoints: susceptible (S) MIC ≤ 8 µL; susceptible, dose-dependent (SDD) MIC 16–32 µL that predicts a poor response to 100 mg a day of fluconazole orally; or resistant (R) MIC > 64 µL. On the basis of previously published data, it appears that resistance occurs in roughly 5% of patients with advanced AIDS. The largest group of failures reported outside of patients with AIDS and OPC consists of patients with fungemia. In both groups, one of the major factors predicting fluconazole resistance is low-dose fluconazole used as prophylaxis.

The clinical significance of fluconazole resistance as defined in the laboratory is not fully known. Most OPC cases described in the literature of fluconazole resistance have been in AIDS patients. The clinical significance of fluconazole resistance was assessed in 50 HIV-positive patients with recurrent OPC in a study by Revankar et al. Resistant yeast was defined as an MIC > 8 µL. Thirty-two of 50 patients were found to have resistant *Candida* (11 had MIC > 32 µL), but almost all patients responded clinically to fluconazole (48/50), which suggests that the clinical efficacy of fluconazole remains high.

**Resistance issues: azole-resistant *Candida* species**

Several mechanisms give rise to resistance to azole drugs. One is mutation in the gene, *ERG11*, which encodes the target enzyme of azoles, ie, lanosterol demethylase. Another resistant mechanism of *Candida* species is overexpression of drug
efflux pumps. Posaconazole, however, is not a substrate for two major pumps, MDR1 and FLU1, that confer resistance to voriconazole or fluconazole.15 In fact, posaconazole may have clinical activity against fluconazole-resistant Candida species.11 Posaconazole has good activity against Candida species that are less susceptible to fluconazole (eg, C. krusei, C. guilliermondii, and C. dublinensis), but is less active against C. glabrata.9 Based on MIC90 values, posaconazole was found to be more potent than fluconazole and equal or more potent than itraconazole, voriconazole, and amphotericin B against these isolates.9 However, more than half of Candida isolates resistant to fluconazole were also less susceptible to posaconazole.16 The clinical significance of these findings is unknown.10

**Pharmacology and pharmacokinetics of posaconazole**

Guidelines developed by the Infectious Diseases Society of America for candidiasis recommend posaconazole for fluconazole-refractory OPC at a dose of 400 mg orally twice daily for three days, followed by 400 mg orally once daily for up to 28 days.6 However, the manufacturer’s dosing information is slightly different. For treatment of OPC, the loading dose is 100 mg (2.5 mL) orally twice daily for one day, then 100 mg orally once daily for 13 days. The manufacturer’s recommendation for treatment of OPC refractory to itraconazole and fluconazole is 400 mg (10 mL) twice a day for a duration based on the severity of the disease and clinical response.17

Posaconazole is given orally. The oral solution is administered during or within 20 minutes of a full meal or a liquid nutritional supplement. Alternatively, the drug can be administered with an acidic carbonated drink. It should be stored at 25°C. There is no dose adjustment recommended for renal or liver failure.5,18 The structural formula is shown in Figure 1.

Following multiple dose administration, steady-state plasma concentrations are attained at 7–10 days. During twice daily dosing of posaconazole over 14 days, mean peak plasma concentrations were achieved on day 1 at five hours and eight hours following the administration of the first and second dose, respectively. On day 14, peak plasma concentrations were observed at 4–6 hours and at 9–11 hours following the administration of the first and second doses, respectively.19 Absorption is influenced by the frequency of doses and meals. Posaconazole is absorbed better if taken with meals, especially high-fat meals. Acidic carbonated beverages also increase absorption.20

Posaconazole is 98% protein-bound, mostly to albumin. It is lipophilic and has a high volume of distribution suggesting extensive extravascular distribution and penetration into body fluids, bone, central nervous system, eye, and pulmonary epithelial lining fluid. A very small percentage of posaconazole is metabolized and the majority of the drug is eliminated from the body unchanged. Less than 30% is metabolized by the liver through glucuronidation and is transformed into biologically inactive metabolites.21 The majority of posaconazole is excreted in the feces up to 120 hours after a dose. Only 13%–14% of posaconazole is excreted in the urine.19 Mean total body clearance is 32 L/hour. The elimination half-life of the parent compound is 35 hours, with a range of 20–66 hours.20

**Efficacy studies in OPC**

The clinical efficacy of posaconazole in OPC was investigated in two major studies done in HIV-positive patients. In a multicenter, randomized, evaluator-blinded trial by Vasquez et al in 2006, posaconazole was compared with fluconazole in the treatment of OPC in HIV-infected patients.22 The primary endpoint was clinical success (cure or improvement) on day 14. This was evaluated in 329 patients. Other secondary endpoints were mycologic success, defined as a quantitative yeast culture yielding 20 colony forming units (cfu)/mL of Candida species and eradication, defined as 0 cfu/mL. Persistence (nonsuccess) was defined as >20 cfu/mL of Candida species. Relapse was defined as 20 cfu/mL of Candida species on day 14 and 20 cfu/mL on day 42. Durability of clinical success was evaluated on day 42. Posaconazole was administered to 178 patients and 172 received fluconazole. Clinical success occurred in 91.7% of posaconazole recipients and in 92.5% of fluconazole recipients, indicating that posaconazole was not inferior to fluconazole. On day 14, mycologic success was 68% in both arms, but by day 42, significantly more posaconazole recipients than fluconazole continued to have mycological success (40.6% versus 26.4%, respectively). Fewer posaconazole recipients than fluconazole experienced clinical relapse (31.5% versus 38.2%). Adverse effects were similar between the treatment arms.22

![Figure 1 Structural formula of posaconazole.](image-url)
The efficacy and safety of oral posaconazole was evaluated in a Phase III, open-label study by Skiest et al in 2007. The study consisted of 176 HIV-infected patients with confirmed esophageal candidiasis or OPC who failed previous fluconazole or itraconazole therapy or had laboratory-confirmed resistant mucosal candidiasis. Posaconazole was administered to 103 subjects at 400 mg twice daily for three days, followed by posaconazole 400 mg once daily for 25 days, and 96 patients received posaconazole 400 mg twice daily for 28 days. There was a clinical response (cure or improvement) in 75.3% of patients after receiving 28 days of posaconazole treatment. Clinical response rates were similar between both arms of the study. Clinical responses were also similar in different patients with baseline isolates resistant to fluconazole, voriconazole, or both. The most common treatment-related adverse events were diarrhea (11%), neutropenia (7%), flatulence (6%), and nausea (6%). Table 1 summarizes the clinical studies with posaconazole in HIV patients.

Few studies have looked at posaconazole as prophylaxis in neutropenic patients. Posaconazole is approved for prophylaxis of emergent filamentous fungi in patients with neutropenia from acute myelogenous leukemia or myelodysplastic syndrome. In a multicenter study published in 2007 by Cornely et al, posaconazole was compared with fluconazole or itraconazole as prophylaxis for invasive fungal infections in patients with prolonged neutropenia. Three hundred and four patients were randomly assigned to receive posaconazole 200 mg three times daily and 298 patients received fluconazole 400 mg daily or itraconazole 200 mg twice daily. Proven or probable invasive fungal infections were reported in seven patients (2%) in the posaconazole group and 25 patients (8%) in the fluconazole or itraconazole group. The majority of fungal infections were caused by Aspergillus species and there was a clear superiority of posaconazole over fluconazole. Invasive candidiasis occurred in three patients who received posaconazole, in two patients in the fluconazole arm, in none in the itraconazole arm, and the results were not statistically significant. This study showed posaconazole to be more effective in preventing invasive fungal diseases and improving survival.

Another international study by Ullmann et al in 2007 looked at prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) on immunosuppressive treatment and compared posaconazole with fluconazole. This was a randomized, double-blind trial including patients who received an allogeneic hematopoietic stem cell transplant and developed GVHD. Posaconazole 200 mg three times daily was administered to 301 patients, and 299 patients received fluconazole 400 mg once daily. Posaconazole was found to be as effective as fluconazole in preventing all invasive fungal infections, but was superior to fluconazole in preventing proven or probable invasive aspergillosis and reducing the rate of deaths related to fungal infections. Colonization with Candida species was assessed and the development of resistance was found to be higher among patients taking fluconazole (17%) than posaconazole (5%).

There have been numerous studies in vitro and in mice showing the potency of posaconazole against different fungi. Pfaffer et al compared the new triazole derivatives, ie, posaconazole, ravuconazole, and voriconazole with itraconazole and amphotericin B against 239 clinical isolates of filamentous fungi. All the new azoles had excellent activity against Aspergillus species, posaconazole was better than voriconazole for Rhizopus, and none of them had activity against Fusarium or Mucor, although other studies showed in vivo activity against a few Fusarium species.

Another study by Sabatelli et al compared the activity of posaconazole with itraconazole, fluconazole, voriconazole, and amphotericin B against 19,000 strains of yeasts and molds. Posaconazole was more active than, or within 1 dilution of, the comparator drugs against 7000 isolates of Candida and Cryptococcus species. Also, posaconazole was active against species of Candida and Aspergillus which showed resistance to fluconazole, voriconazole, 

Table 1 Evidence for use of posaconazole in HIV patients with OPC and/or esophageal candidiasis

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Study population</th>
<th>Posaconazole</th>
<th>Fluconazole</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skiest et al&lt;sup&gt;11&lt;/sup&gt;</td>
<td>Phase III, open-label</td>
<td>OPC or EC with refractory disease to fluconazole, 199 patients</td>
<td>400 mg bid for 3 days, then 400 mg qd for 25 days or 400 mg bid for 28 days</td>
<td>200 mg first day, then 100 mg qd for 13 days</td>
<td>75% clinical response</td>
</tr>
<tr>
<td>Vasquez et al&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Randomized, evaluator-blinded</td>
<td>OPC, 350 patients</td>
<td>200 mg first day, then 100 mg qd for 13 days</td>
<td>200 mg first day, then 100 mg qd for 13 days</td>
<td>Posaconazole as effective as fluconazole, CI 95%</td>
</tr>
</tbody>
</table>

**Abbreviations**: EC, esophageal candidiasis; OPC, oropharyngeal candidiasis; qd, once daily; CI, confidence interval.
and amphotericin B, and was much more active than other triazoles against Zygomycetes.

Posaconazole efficacy was studied in mice against *C. glabrata* isolates with various susceptibilities to fluconazole by Spreghini et al in 2008. Posaconazole was found to be significantly effective against all the strains.

**Posaconazole safety and tolerability**

In a study by Vazquez et al, 64% of posaconazole therapy recipients (114/178) and 68% of fluconazole therapy recipients (117/172) reported adverse events during 14 days of OPC treatment. In the posaconazole and fluconazole treatment groups, only 25% and 24% of these events were determined to be posaconazole-related, respectively. The most commonly reported adverse events were diarrhea (15% posaconazole and 20% fluconazole groups) and nausea (17% posaconazole and 15% fluconazole groups). Other reported adverse events (>5%) in the posaconazole treatment group included headache (13%), vomiting (11%), fever (10%), abdominal pain (8%), and dizziness (6%), that were similar to rates reported in the fluconazole treatment arm. Other serious reported adverse events in the posaconazole arm included asthenia, respiratory insufficiency, and lymphadenopathy, but none of these events were associated with posaconazole therapy.

In a study by Skiest et al, adverse events were reported in 49% of the 199 subjects in the intent-to-treat posaconazole OPC 28-day treatment arms. Commonly reported adverse events included nausea (12%), diarrhea (21%), flatulence (11%), abdominal pain (10%), headache (9%), vomiting (9%), dizziness (7%), fatigue (6%), and rash (6%). Neutropenia (n = 28) was the most common reported adverse event during posaconazole therapy but only 7% were possibly or probably associated with posaconazole therapy. QT prolongation, epistaxis, rash, edema, hypersensitivity, vomiting, or laboratory abnormalities led to discontinuation of posaconazole therapy in 11 subjects. Overall, many of these adverse events are common in HIV-infected or immunocompromised patients due to the disease state and other therapies utilized, including antiretroviral agents and chemotherapy.

While generally well tolerated, patients receiving posaconazole therapy for OPC should be monitored for liver and cardiac dysfunction. Posaconazole should be used with caution in patients with a history or development of adrenal insufficiency, liver dysfunction or failure, and QT interval prolongation. During posaconazole therapy for OPC, liver function tests including bilirubin levels may rise due to cholestasis. Liver enzymes should be periodically monitored. Serum electrolyte levels, specifically potassium, magnesium, and calcium, should be monitored due to risk of hypocalcemia (9%), hypokalemia (3%), and hypomagnesemia (18%) during posaconazole therapy. As with any medication, patients should be screened prior to use for previous intolerance or contraindications to posaconazole or similar triazole-class agents.

Administration of posaconazole with a cytochrome P450 3A4 substrate should be evaluated prior to start of therapy. Posaconazole has no significant effect on CYP enzymes except CYP3A4. In a study done by Wexler et al, posaconazole inhibits CYP3A4 at submicromolar concentrations, and other enzymes were not inhibited (CYP1A2, 2A6, 2C9, 2C19, and 2D6). All azoles inhibit CYP3A4, but the other azoles inhibit some of the other enzymes too, eg, fluconazole and itraconazole inhibit 1A2 and 2C, whereas voriconazole inhibits 2C9 and 2C19. This means fewer drug inhibitions by posaconazole overall. Contraindications to taking posaconazole are the concurrent use of sirolimus, ergot alkaloids, and the CYP3A4 substrates terbinafine, astemizole, cisapride, pimozine, halofantrine, and quinidine. Caution should be exercised in patients with hypersensitivity to other azoles and potentially proarrhythmic conditions. Serious side effects reported include adrenal insufficiency, cholestasis, hyperbilirubinemia, increased liver enzymes, liver damage, liver failure, and prolonged QT interval. One study found that adverse effects were not dose-dependent. Depending on the degree of interaction, alternative therapy or dosage adjustments may be necessary during posaconazole therapy. Additionally, the coadministration of posaconazole and agents with known increased risk of QT prolongation or liver dysfunction should be used with caution. Due to risk of ergotism, administration of ergot alkaloids with posaconazole is contraindicated. Coadministration of posaconazole with acid-blocking agents should be evaluated due to their potential to decrease absorption of posaconazole and therefore decrease serum posaconazole levels during OPC treatment.

**Patient satisfaction, acceptability, adherence, and uptake**

Outpatient and inpatient compliance along with patient satisfaction and quality of life with posaconazole OPC therapy is dependent on a variety of factors, including incidence of adverse events, efficacy, dosage frequency, and drug cost. Many of these factors are similar for posaconazole and fluconazole OPC treatment regimens.
As reported by Skiest et al and Vazquez et al, rates of common adverse events such as nausea, vomiting, and diarrhea are similar between fluconazole and posaconazole for OPC therapy.11,22 In the study by Vazquez et al, 88% and 89% of enrolled patients with OPC completed the treatment phase of posaconazole and fluconazole therapy, respectively, as prescribed. Reasons determined for early discontinuation of therapies included adverse events (4% for both treatment groups), treatment failures (2% for both treatment groups), and noncompliance or loss to follow-up, including death (6% posaconazole group and 5% fluconazole group).22 In the study by Skiest et al, therapy was completed in 75% of the 199 HIV-infected subjects in an intent-to-treat posaconazole OPC 28-day treatment regimen. Reasons for discontinuation of treatment were adverse events (23%), treatment failure (5%), non-compliance (12%), death (4%), and other (3%).

Based on currently published reports, duration of therapy and dosing schedule is similar for both posaconazole and fluconazole for OPC treatment. Posaconazole OPC treatment regimens generally involve either daily or twice daily dosing. This dosing frequency is significantly less compared with standard posaconazole therapy recommended at three to four times daily for more serious systemic infections. Patient education should include an evaluation of a patient’s dietary intake, including timing of dose with meals. Since it is recommended that posaconazole therapy be administered with food, posaconazole frequency may be adjusted in certain patients to maximize compliance of therapy with food intake. While posaconazole therapy has been shown to be efficacious in treatment of OPC, posaconazole therapy may not be feasible, and alternative therapy may need to be evaluated if a patient has difficulty with oral medication absorption due to factors such as significant nausea and vomiting, limited oral intake or use of acid-blocking agents, or gastrointestinal tract dysfunction, including ileus and mucositis.

Whether therapy is prescribed for outpatient or inpatient use, the patient’s financial and insurance status may be a barrier to posaconazole therapy. A generic formulation of posaconazole is not currently available in the US, unlike other triazole agents such as fluconazole and itraconazole. Certain insurance companies or institutions may require prior authorization based on formulary restrictions. Additionally, the immediate availability of posaconazole suspension at certain medical centers, clinics, and community pharmacies may be limited and dependent on regional patient populations. Overall, to increase patient compliance with OPC posaconazole therapy, patients should receive information related to the purpose of treatment, directions for administration, and potential side effects of posaconazole therapy.

Conclusions
Posaconazole is effective in prophylaxis against invasive fungal infections in selected patient populations, as well as for the treatment of some fungi, especially Aspergillus and some Zygomycetes. Posaconazole has been shown to be more effective than fluconazole or itraconazole for prevention of invasive fungal infections in patients with neutropenia from chemotherapy, leukemia, or myelodysplastic syndrome. In the treatment of OPC, posaconazole is at least as effective as fluconazole in HIV patients with OPC. Posaconazole is effective in fluconazole/itraconazole-resistant OPC and in the treatment of non-OPC fluconazole-resistant Candida species infections. Side effects of posaconazole are similar to fluconazole in most studies, but administration and absorption remain a major concern. Further clinical studies of posaconazole are warranted to extend the range of approved treatment of posaconazole. However, for the vast majority of OPC cases fluconazole remains the drug of choice due to its efficacy and lower cost.

Disclosure
The authors report no conflicts of interest.

References


